EP1966113A1 - Procédé pour produire un composé chlorure de méthyle alpha-chiral sous une forme pure - Google Patents
Procédé pour produire un composé chlorure de méthyle alpha-chiral sous une forme pureInfo
- Publication number
- EP1966113A1 EP1966113A1 EP06841346A EP06841346A EP1966113A1 EP 1966113 A1 EP1966113 A1 EP 1966113A1 EP 06841346 A EP06841346 A EP 06841346A EP 06841346 A EP06841346 A EP 06841346A EP 1966113 A1 EP1966113 A1 EP 1966113A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- compound
- mixtures
- preparation
- optically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 chloromethyl compound Chemical class 0.000 title abstract description 6
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 84
- 238000009835 boiling Methods 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 239000012535 impurity Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims description 37
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 35
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 15
- 238000007700 distillative separation Methods 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000006227 byproduct Substances 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 239000010409 thin film Substances 0.000 claims description 4
- 238000001944 continuous distillation Methods 0.000 claims description 3
- 238000000199 molecular distillation Methods 0.000 claims description 3
- 239000011552 falling film Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 4
- 238000000926 separation method Methods 0.000 abstract description 4
- 238000004821 distillation Methods 0.000 abstract description 3
- 239000013067 intermediate product Substances 0.000 abstract 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000007872 degassing Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000000526 short-path distillation Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- RMZAYIKUYWXQPB-UHFFFAOYSA-N trioctylphosphane Chemical compound CCCCCCCCP(CCCCCCCC)CCCCCCCC RMZAYIKUYWXQPB-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/34—Separation; Purification; Stabilisation; Use of additives
- C07C41/40—Separation; Purification; Stabilisation; Use of additives by change of physical state, e.g. by crystallisation
- C07C41/42—Separation; Purification; Stabilisation; Use of additives by change of physical state, e.g. by crystallisation by distillation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
- C07C41/22—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of halogens; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the present invention relates to a process for preparing a specific ⁇ -chiral chloromethyl compound in pure or enriched form by distillative separation of said compound from mixtures containing this compound and higher-boiling impurities.
- the subject ⁇ -chiral chloromethyl compound is in crystalline form at room temperature and is a central intermediate for the preparation of a class of drugs.
- EP 0 678 503 describes ⁇ -amino-Y-hydroxy- ⁇ -aryl-alkenecarboxamides which have renin-inhibiting properties and can be used as anti-hypertensive agents in pharmaceutical preparations.
- WO 01/09083 describes a process for the preparation of said ⁇ -amino- ⁇ -hydroxy- ⁇ -aryl-alkencarboxamide.
- the central intermediate is the compound of the formula (Ia)
- chlorinating reagents carbon tetrachloride and trioctylphosphine are used.
- the resulting reaction product is purified by extractive workup first by flash chromatography and then by crystallization from hexane at -50 ° C.
- the object of the present invention was thus to provide a process for the preparation of the compound of formula (I) in pure or enriched form, which does not have the disadvantages mentioned above and makes the compound of formula (I) available in high yield and purity.
- Particularly suitable mixtures of substances to be used according to the invention are those which contain from about 25 to about 99% by weight, preferably from about 50 to about 98% by weight, more preferably from about 75 to about 97% by weight, even more preferably from about 85% to about 97%, and most preferably from about 90% to about 97%, by weight of the compound of formula (I) or the compound of formula (Ia).
- the abovementioned mixtures also contain higher-boiling impurities and, if appropriate, even lower-boiling impurities, for example solvent residues or low molecular weight by-products of the preceding synthesis stages.
- the process according to the invention serves to prepare optically active compounds of the formula (I) or (Ia) in pure or enriched form.
- the term in pure or enriched form means either that the compound of the formula (I) or (Ia) is obtained in pure form or is obtained in the form of a substance mixture which has a higher content of the respective compound of the formula (I) or (Ia), as the substance mixtures used in the invention.
- the compound of the formula (I) or (Ia) in pure form is understood to mean the particular compound having a purity of at least about 98% by weight, preferably about 99.5 to about 99.9% by weight.
- the compound of the formula (I) or (Ia) in enriched form is preferably to be understood as meaning mixtures of substances which are from about 90 to about 99.9% by weight, preferably from about 95 to about 99.9 Wt .-%, particularly preferably from about 95 to about 99.9 wt .-% and most preferably from about 97 to about 99.9 wt .-% of the compound of formula (I) or (Ia) consists ,
- the pure or enriched compounds of the formula (I) or (Ia) are obtained in optically active form.
- the enantiomeric excess of the respective compound of the formula (I) or (Ia) obtained preferably corresponds largely to that of the compound of the formula (I) or (Ia) used in the substance mixture used according to the invention.
- the compound of the formula (I) or (Ia) is preferably obtained in pure or enriched form with an enantiomeric excess which is at least 85%, more preferably at least 90%, most preferably at least 95% of the enantiomeric excess of the compound of the formula (I ) or (Ia) is.
- the process according to the invention is preferably carried out such that the distillative separation is carried out at a pressure in the range from about 0.0001 mbar to about 10 mbar, preferably from about 0.001 to about 5 mbar, and more preferably from about 0.001 to about 0.1 mbar.
- the distillative separation according to the invention can, depending on the selected pressure, be carried out at temperatures in the range of about 50.degree. C. to about 250.degree. C., preferably about 80 to about 220.degree.
- the separation according to the invention is preferably carried out in the form of a continuous distillation.
- Particularly preferred embodiments of the method according to the invention are so-called short-path or molecular distillation in which the paths between the evaporator surfaces and the condenser surfaces are as short and straight as possible.
- Suitable evaporators are in particular short-path evaporator, thin-film evaporator or falling-film evaporator.
- commercially available molecular distillation apparatuses such as those offered by specialist dealers. Alternatively, a rectification in the fine vacuum range is possible.
- the process according to the invention allows the preparation of the compound of the formula (I) or (Ia) in pure or enriched form. Accordingly, the present invention also relates to a process for purifying the compound of the formula (I) or (Ia) by distillative removal of the compound of the formula (I) from mixtures comprising the optically active compound of the formula (I) and relatively high-boiling impurities.
- the mixtures of substances to be used according to the invention may also contain lower-boiling compounds, ie compounds which have a lower boiling point than the compound of the formula (I) or (Ia).
- lower-boiling compounds for example solvent residues, excess reagents or low molecular weight by-products of the preceding synthesis steps, can be obtained as prefractions within the scope of the distillative separation according to the invention and thus also be separated from the compound of formula (I) or (Ia).
- the term higher-boiling impurities is to be understood as meaning those compounds which have a higher boiling point than the compound of the formula (I) or (Ia).
- the above-mentioned higher-boiling compounds can also be by-products of the synthesis sequence for the preparation of the compound of the formula (I).
- the mixtures of substances to be used according to the invention can be dimerization products of the compound of the formula (I), for example the compound of the formula (III)
- higher-boiling dimerization products are, for example, those in which the two halves of the molecule are linked to one another via the aromatic compounds by a disulphide bridge.
- the present invention therefore relates to the process described above, which is characterized in that use is made of mixtures which are obtainable by reacting an optically active alcohol of the formula (M)
- the present invention relates to a process for preparing optically active compounds of the formula (I)
- step b) distillative separation of the compound of the formula (I) from the mixtures of substances obtained in step a) containing the optically active compound of the formula (I) and higher-boiling impurities.
- the present invention also relates to a process for the preparation of the compound of the formula (I) or (Ia) by reacting the compound of the formula (II) or (IIa) with thionyl chloride and N, N-dimethylformamide.
- the optically active compound of the formula (II) and thionyl chloride preferably in a molar ratio in the range of about 1 to 1 to about 1 to 5, more preferably from about 1 to 1, 1 to about 1 to 2.
- the reaction is carried out in the presence of N, N-dimethylformamide, wherein N, N-dimethylformamide and thionyl chloride are preferably used in a molar ratio in the range of about 0.01 to 1 to about 1 to 1, particularly preferably in the range of about 0, 03 to 1 to 0.1 to 1.
- the reaction is preferably carried out by halogenating a solution of the optically active alcohol of the formula (II) in a suitable solvent which is inert under the reaction conditions, for example benzene, toluene, xylenes, ethers such as diethyl ether, THF, dioxane and the like Solvents, such as methylene chloride, chloroform, 1, 2-dichloroethane and the like more, preferably in toluene, together with the selected amount of N, N-dimethylformamide presents and the selected amount of thionyl chloride at a temperature of about 80 to about 100 ° C added.
- the reaction is usually completed after about one to about 5 hours, often after about 2 hours.
- the process according to the invention for the preparation of the compound of the formula (I) or (Ia) in pure or enriched form provides an unexpectedly efficient access to said compound, especially to the compound of the formula (Ia) in a form which satisfies the requirements of a drug intermediate are to take into account. It is clearly superior to the known processes for purifying the compounds mentioned by crystallization, in particular with regard to the number of process steps and the yield and purity of the product, since especially higher-boiling, structurally similar impurities with a high tendency to crystallize are insufficiently separated from the desired product by conventional crystallization ,
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
L'invention concerne un procédé pour produire un composé chlorure de méthyle α-chiral spécifique sous une forme pure ou enrichie, consistant à séparer, par distillation, ce composé qui est contenu dans un mélange de substances actives renfermant également des impuretés à point d'ébullition élevé. Le composé chlorure de méthyle α-chiral spécifique selon l'invention se présente sous une forme cristalline à température ambiante, et constitue un produit intermédiaire essentiel pour produire une classe de médicaments.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06841346A EP1966113A1 (fr) | 2005-12-23 | 2006-12-13 | Procédé pour produire un composé chlorure de méthyle alpha-chiral sous une forme pure |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05112933 | 2005-12-23 | ||
| PCT/EP2006/069632 WO2007074062A1 (fr) | 2005-12-23 | 2006-12-13 | Procédé pour produire un composé chlorure de méthyle alpha-chiral sous une forme pure |
| EP06841346A EP1966113A1 (fr) | 2005-12-23 | 2006-12-13 | Procédé pour produire un composé chlorure de méthyle alpha-chiral sous une forme pure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1966113A1 true EP1966113A1 (fr) | 2008-09-10 |
Family
ID=37951840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP06841346A Withdrawn EP1966113A1 (fr) | 2005-12-23 | 2006-12-13 | Procédé pour produire un composé chlorure de méthyle alpha-chiral sous une forme pure |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080306311A1 (fr) |
| EP (1) | EP1966113A1 (fr) |
| JP (1) | JP2009520753A (fr) |
| CN (1) | CN101346333A (fr) |
| WO (1) | WO2007074062A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1400961B1 (it) * | 2010-06-04 | 2013-07-05 | Chemo Iberica Sa | Processo per la produzione di aliskiren |
| TW201202178A (en) * | 2010-06-04 | 2012-01-16 | Chemo Iberica Sa | Process for producing Aliskiren |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US700978A (en) * | 1902-02-20 | 1902-05-27 | Isaac E Palmer | Hammock. |
| JP2727688B2 (ja) * | 1989-09-22 | 1998-03-11 | 住友化学工業株式会社 | 光学活性なベンジル誘導体およびその製法 |
| US5606078A (en) * | 1994-04-18 | 1997-02-25 | Ciba-Geigy Corporation | 3,5-Disubstituted tetrahydrofuran-2-ones |
| IT1276165B1 (it) * | 1995-11-24 | 1997-10-27 | Caffaro Spa Ind Chim | Procedimento per la sintesi enantioselettiva di derivati chirali di s-3-(4'-tert-butil)-fenil-2-metil propilammina, fungicidi sistemici |
| JP3915253B2 (ja) * | 1998-06-12 | 2007-05-16 | 三菱化学株式会社 | ω−ハロゲノアルキルスチレン誘導体の製造方法 |
| PT1303478E (pt) * | 2000-07-25 | 2004-10-29 | Speedel Pharma Ag | Processo para a preparacao de alcanoilamidas substituidas |
-
2006
- 2006-12-13 EP EP06841346A patent/EP1966113A1/fr not_active Withdrawn
- 2006-12-13 JP JP2008546386A patent/JP2009520753A/ja active Pending
- 2006-12-13 WO PCT/EP2006/069632 patent/WO2007074062A1/fr not_active Ceased
- 2006-12-13 CN CNA2006800489454A patent/CN101346333A/zh active Pending
- 2006-12-13 US US12/158,543 patent/US20080306311A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2007074062A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101346333A (zh) | 2009-01-14 |
| JP2009520753A (ja) | 2009-05-28 |
| US20080306311A1 (en) | 2008-12-11 |
| WO2007074062A1 (fr) | 2007-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0072514B1 (fr) | Procédé pour l'halogénation de composés organiques | |
| DE4100441A1 (de) | Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol | |
| WO2009033870A1 (fr) | Procédé de production en continu de menthol sous une forme pure ou enrichie | |
| EP2064169A1 (fr) | Recuperation de ligands bis(diarylphenol) lors de la production d'isopulegol | |
| EP0026311B2 (fr) | Procédé de préparation d'epsilon-caprolactone très pur | |
| WO2009003796A1 (fr) | Procédé de production de citral (néral et/ou géranial) par isomérisation d'isocitrals | |
| WO2007074062A1 (fr) | Procédé pour produire un composé chlorure de méthyle alpha-chiral sous une forme pure | |
| EP1415964B1 (fr) | Procédé pour la séparation de mélanges contenant du m- et p-dichlorobenzène | |
| EP1999102B1 (fr) | Procede de fabrication de n,n-dimethylaminoethoxyethanol | |
| DE69219582T2 (de) | Neue verbindung und trennungsreagenz | |
| EP0057844A1 (fr) | Procédé de préparation de chlorures de polychlorobenzoyle | |
| WO2002042286A1 (fr) | Procede d'acylation continue de derives d'esters de chromanol | |
| DE112020004177B4 (de) | Verfahren zur herstellung des natriumsalzes von 4-[[(1r)-2-[5-(2-fluor-3-methoxyphenyl)-3-[[2-fluor-6-(trifluormethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2h)-pyrimidinyl]-1-phenylethyl]amino]butansäure (elagolix-natriumsalz) und zwischenstufen dieses verfahrens | |
| DE69814462T2 (de) | 1,7-dibromodibenzosuberon und verfahren zur herstellung | |
| EP0192148B1 (fr) | Dérivés du 2,4-dichlorothiazole et procédé pour leur préparation | |
| WO2001014308A1 (fr) | Procede pour produire de l'anhydride phtalique conforme aux specifications | |
| EP0224902B1 (fr) | Procédé de préparation de D-threo-1-(p-methylsulfonylphenyl)-2-dichloracétamido-propandiol-1,3-(Thiamphénicol) et utilisation de produits intermédiaires appropriés | |
| EP0936220B1 (fr) | Procédé pour la préparation catalytique des 3-isochromanones commencant des phthalanes | |
| DE69117137T2 (de) | 2-Chlorpropionaldehyd-Trimer und Verfahren zur Herstellung davon | |
| DE2164662A1 (de) | Indanderivate und Verfahren zu ihrer Herstellung | |
| EP0162235B1 (fr) | Enantiomères purs de diols mono-protégés par un groupe acétal, leur préparation et utilisation | |
| DE3607993A1 (de) | Verfahren zur herstellung von diaziridinen und produkte daraus | |
| EP0261388B1 (fr) | Procédé de séparation de diastéréomères d'esters d'acides cyclopropanecarboxyliques | |
| DE3842029A1 (de) | 2-(3'-halogen-n-propyl)-2,5,7,8-tetramethyl-6-chromanole, verfahren zu deren herstellung sowie zwischenprodukte dieses verfahrens | |
| DE2950436A1 (de) | 1 alpha -aethyl-1 beta - eckige klammer auf 2'-(methoxycarbonyl)-aethyl eckige klammer zu -9-brom-1,2,3,4,6,7,12,12b -octahydroindolo eckige klammer auf 2,3-a eckige klammer zu chinolizinderivate, verfahren zur herstellung derselben bzw. von 10-bromvincamin und 10-brom-14-epivincamin, erstere enthaltende arzneimittel sowie 1-aethyl-1- eckige klammer auf 2'- (acetoxy)-2'-(methoxycarbonyl)-aethyl eckige klammer zu -9-brom-1,2,3,4,6,7- hexahydro-12h-indolo eckige klammer auf 2,3-a eckige klammer zu chinolizin-5- iumperchlorat und 1-aethyl-1- eckige klammer auf 2'-(hydroxy)-2'-(methoxycarbonyl)- aethyl eckige klammer zu -9-brom-1,2,3,4, 6,7-hexahydro-12h-indolo eckige klammer auf 2,3-a eckige klammer zu chinolizin- 5-iumperchlorat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20080723 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| 17Q | First examination report despatched |
Effective date: 20101118 |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20150701 |